← Leaderboards
M.r.k. (dickon) Alley
An2 Therapeutics, Inc.
$9,235,577
Attributed
$9,235,577
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.3M · FY2022–25$5M$3.8M$2.5M$1.3M$0
'22
'23
'24
'25
Funding mix
By agency
NIH$9,235,577 · 1
By mechanism
N01$9,235,577 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Therapeutic Development”
- Suma Babu · Massachusetts General Hospital$22,928,184
- Sabrina Paganoni · Massachusetts General Hospital$22,928,184
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Supriya Menezes · The Emmes Company, Llc$18,394,958
- Daniel Hunter Reirden · Westat, Inc.$16,121,731
- Kevin V Grimes · Stanford University$14,783,804
Research focus
Therapeutic DevelopmentBurkholderia PseudomalleiChemistryEfficacy EvaluationEmerging Communicable DiseasesMelioidosisNovel TherapeuticsPre-ClinicalProduct DevelopmentResearch And DevelopmentSafety AssessmentTherapeutic CandidateAdvanced DevelopmentManufactureAntibiotic ResistanceBiodefenseNational Institute Of Allergy And Infectious DiseaseCandidate SelectionCategoriesResearch SupportClinical AssessmentsPathogenPathway InteractionsLead Optimization
Grant awards (4)
Development of a Novel Therapeutic for Melioidosis$456,766
N01 · FY2025 · AI · contact PI
Development of a Novel Therapeutic for Melioidosis$3,821,365
N01 · FY2024 · AI · contact PI
DEVELOPMENT OF A NOVEL THERAPEUTIC FOR MELIOIDOSIS$651,041
N01 · FY2023 · AI · contact PI
DEVELOPMENT OF A NOVEL THERAPEUTIC FOR MELIOIDOSIS$4,306,405
N01 · FY2022 · AI · contact PI